Decoy Therapeutics Inc Com Par 0.0001 New DCOY Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.13 up $0.01, 0.88% at close Nov 6
Last close · Previous close $1.12
- Market cap
- $601.07KAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$1.13down $0.42, 27.10%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.12Nov 5
- Volume17.68KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume60.29KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.90 to $16.92; now $1.13
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
DCOY trailed the S&P 500 in both periods.
| Period | DCOY and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DCOY: down 27.1% S&P 500: down 5.6% | DCOY trailed the S&P 500 by 21.5 percentage points Trailed |
| 3M | DCOY: down 72.2% S&P 500: down 4.1% | DCOY trailed the S&P 500 by 68.1 percentage points Trailed |
DCOY trailed the S&P 500 in both periods.
| Period | DCOY and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DCOY: down 27.1% S&P 500: down 5.6% | DCOY trailed the S&P 500 by 21.5 percentage points Trailed |
| 3M | DCOY: down 72.2% S&P 500: down 4.3% | DCOY trailed the S&P 500 by 67.9 percentage points Trailed |
All-time high
$15.00
Closing high on . Now 92.5% below that record.
Split-adjusted daily closes since Jan 7, 2026.
Stock splits
1
1-for-12 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- 2.6×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −1,384.95%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - −$7.69MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own DCOY DCF in Excel. Value Decoy Therapeutics Inc Com Par 0.0001 New with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $227.63K
- Net income
- −$14.45M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$972.12K | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$1.46M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$1.71M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$957.83K | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$873.47K | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$8.98M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$2.22M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $227.63K | −$2.37M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $1.84M | −$12.77M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$31.61M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$12.54M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$5.58M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | −$12.52M | Paused See the note under the price. |
Margins
- Gross 100.0%
- Operating −6,421.3%
- Net −6,347.9%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$8.32MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$8.32MLast 12 months
- Capital spending$0.00Last 12 months
- −3,657.1%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $15.10MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $8.29MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$8.29MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 1.83As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −315.2%Last 12 months
Over the last 12 months, Decoy Therapeutics Inc Com Par 0.0001 New lost money: its net loss was 315.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −167.2%Last 12 months
Over the last 12 months, Decoy Therapeutics Inc Com Par 0.0001 New’s net loss was 167.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Decoy Therapeutics Inc Com Par 0.0001 New
Decoy Therapeutics Inc Com Par 0.0001 New
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Texas, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
DCOY news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
DCOY stock FAQ
What is DCOY stock’s price today?
Decoy Therapeutics Inc Com Par 0.0001 New (DCOY) traded at $1.13 at the close on , up $0.01 (0.88%) from the previous close of $1.12. Over the past 52 weeks it has traded between $0.90 and $16.92.
What is Decoy Therapeutics Inc Com Par 0.0001 New’s market cap?
Decoy Therapeutics Inc Com Par 0.0001 New’s market capitalization is about $601.1 thousand. That’s Tiingo’s daily market cap for , at that day’s closing price of $1.13 (how market cap works).
How much revenue does Decoy Therapeutics Inc Com Par 0.0001 New make?
Decoy Therapeutics Inc Com Par 0.0001 New reported $227.6 thousand of revenue over the four quarters to . In its latest quarter (Q2 FY26, ended ) revenue was $227.6 thousand.
Is Decoy Therapeutics Inc Com Par 0.0001 New profitable?
Not over the four quarters to . Decoy Therapeutics Inc Com Par 0.0001 New reported a net loss of $14.4 million across those four quarters on $227.6 thousand of revenue.
Does DCOY pay a dividend?
Decoy Therapeutics Inc Com Par 0.0001 New hasn’t paid a dividend in the last twelve months.
What is DCOY’s 52-week high and low?
Over the past 52 weeks DCOY has traded as low as $0.90 and as high as $16.92. At $1.13 at the close on , it is 93.3% below that high and 25.5% above the low.
What is DCOY’s all-time high?
DCOY’s highest closing price was $15.00 on , adjusted for stock splits. At $1.13 at the close on , it is 92.5% below that record.
Has DCOY stock ever split?
Yes, once: 1-for-12 on .
What sector and industry is Decoy Therapeutics Inc Com Par 0.0001 New in?
Decoy Therapeutics Inc Com Par 0.0001 New is in the Healthcare sector and the Biotechnology industry, and is headquartered in Texas, USA.
What exchange does DCOY trade on?
Decoy Therapeutics Inc Com Par 0.0001 New trades on the Nasdaq under the ticker symbol DCOY. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.